Improving Biopharmaceutical Manufacturing Efficiency Through an End-to-End Continuous Production System
First written in FY2020-Q1. 3 of 5 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2024.
0 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「In the biopharmaceutical CDMO business, development of a continuous manufacturing system using a 500 L culture tank is under way at the FDB site, and high-density cell culture for 40 consecutive days was achieved in the culture process for antibody drugs.」
The company reached a specific technology development milestone by achieving 40 consecutive days of high-density cell culture for antibody drugs using a 500 L tank in its end-to-end continuous manufacturing system. - FY2023AdvancedAnnual report
「The company will also make strategic investments in the United States, the world’s largest biopharmaceutical market, and establish active pharmaceutical ingredient manufacturing capabilities using continuous manufacturing systems in both the European and US markets. Following the company’s UK site, it will install equipment at its Texas site in the United States capable of GMP manufacturing using a continuous manufacturing system.」
The plan is progressing to establish continuous GMP manufacturing capabilities for active pharmaceutical ingredients in both the European and US markets by installing the end-to-end continuous manufacturing system in Texas, following its introduction in the United Kingdom. - FY2023-Q2RestatedAnnual report
「In June 2022, the company announced that it would invest a total of ¥200 billion to expand equipment at its Danish site to meet strong demand for contract manufacturing of antibody drugs and install a commercial continuous manufacturing system at its Texas, U.S. site. The system will provide GMP manufacturing equipment capable of integrated active pharmaceutical ingredient production from cell culture through purification.」
The company has reconfirmed its plan to install commercial GMP equipment at its Texas site in the United States for the end-to-end continuous manufacturing system. - FY2023-Q1AdvancedAnnual report
「In June 2022, the company announced that it would invest a total of ¥200 billion to expand equipment at its Danish site to meet strong demand for contract manufacturing of antibody drugs and install a commercial continuous manufacturing system at its Texas, U.S. site. The system will provide GMP manufacturing equipment capable of integrated active pharmaceutical ingredient production from cell culture through purification.」
The plan to install a commercial continuous manufacturing system as a GMP manufacturing facility at the company’s Texas site in the United States has taken concrete shape. - FY2020-Q1First statedAnnual report
「In June 2019, the company announced that it had developed the industry's first high-performance, high-efficiency continuous manufacturing system covering the entire process from cell culture to purification and would begin contract process development services in autumn of that year.」
The company has developed a high-performance, high-efficiency system that enables continuous processing from cell culture through purification, and plans to use it for contract process development services.